Clearbridge Health’s Strategic Share Issue: A Potential Game Changer for Investors

Clearbridge Health Limited, a prominent player in Singapore’s healthcare sector, has announced a significant development that could potentially influence its stock valuation. The company received a listing and quotation notice from the Singapore Exchange Securities Trading Limited (SGX-ST) for its proposed rights issue, which involves the issuance of up to 1,279,125,560 new ordinary shares on the Catalist Board.

Key Points from the Announcement

• Clearbridge Health Limited’s board has confirmed receiving the listing and quotation notice (LQN) from SGX-ST as of 25 October 2024, which facilitates the dealing in, listing, and quotation for the proposed new shares.
• The rights issue was approved by shareholders during the extraordinary general meeting held on 23 October 2024.
• The LQN is conditional upon the company meeting SGX-ST’s listing requirements.

Implications for Shareholders

This development is crucial for shareholders and potential investors. The rights issue aims to raise capital, which could impact the company’s financial strategy and market position. However, the company cautions that the LQN should not be seen as an endorsement of the rights issue’s merits or the company’s securities.

Important Advisory

Shareholders and investors are advised to exercise caution when trading shares, as there is no certainty that the rights issue will be completed as planned. The company will provide updates on any further developments to ensure transparency and informed decision-making among investors.

The announcement has been reviewed by the company’s sponsor, ZICO Capital Pte. Ltd., but not by SGX-ST, which assumes no responsibility for its contents.

Contact Information

For inquiries, shareholders can reach out to Ms. Goh Mei Xian at ZICO Capital Pte. Ltd., located at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, or by calling (65) 6636 4201.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research and consult with professional advisers before making investment decisions.